CL2023000196A1 - Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y métodos de uso de los mismos - Google Patents

Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y métodos de uso de los mismos

Info

Publication number
CL2023000196A1
CL2023000196A1 CL2023000196A CL2023000196A CL2023000196A1 CL 2023000196 A1 CL2023000196 A1 CL 2023000196A1 CL 2023000196 A CL2023000196 A CL 2023000196A CL 2023000196 A CL2023000196 A CL 2023000196A CL 2023000196 A1 CL2023000196 A1 CL 2023000196A1
Authority
CL
Chile
Prior art keywords
dihydroimidazolone
tetrahydropyrazolo
pyridinyl
pyrazinyl
compounds
Prior art date
Application number
CL2023000196A
Other languages
English (en)
Spanish (es)
Inventor
Ren Zaifang
Sun Xuefeng
Zhou Jingye
Xu Qing
Original Assignee
Eccogene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eccogene Inc filed Critical Eccogene Inc
Publication of CL2023000196A1 publication Critical patent/CL2023000196A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CL2023000196A 2020-07-20 2023-01-19 Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y métodos de uso de los mismos CL2023000196A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2020102955 2020-07-20
CN2021070120 2021-01-04

Publications (1)

Publication Number Publication Date
CL2023000196A1 true CL2023000196A1 (es) 2023-09-15

Family

ID=77167918

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023000196A CL2023000196A1 (es) 2020-07-20 2023-01-19 Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y métodos de uso de los mismos

Country Status (16)

Country Link
US (3) US12037339B2 (cg-RX-API-DMAC7.html)
EP (1) EP4182020A1 (cg-RX-API-DMAC7.html)
JP (3) JP7569443B2 (cg-RX-API-DMAC7.html)
KR (2) KR20260040657A (cg-RX-API-DMAC7.html)
CN (8) CN122516177A (cg-RX-API-DMAC7.html)
AU (2) AU2021311567B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023000932A2 (cg-RX-API-DMAC7.html)
CA (1) CA3186217A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023000196A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023001407A2 (cg-RX-API-DMAC7.html)
IL (2) IL299704B1 (cg-RX-API-DMAC7.html)
MX (1) MX2023000943A (cg-RX-API-DMAC7.html)
PE (1) PE20230854A1 (cg-RX-API-DMAC7.html)
PH (1) PH12023550130A1 (cg-RX-API-DMAC7.html)
UA (1) UA130727C2 (cg-RX-API-DMAC7.html)
WO (1) WO2022017338A1 (cg-RX-API-DMAC7.html)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190060A1 (ar) 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
WO2022052958A1 (en) * 2020-09-10 2022-03-17 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
US12643905B2 (en) 2021-07-23 2026-06-02 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US12479854B2 (en) 2021-07-29 2025-11-25 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US20240366639A1 (en) * 2021-08-12 2024-11-07 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
SI4408840T1 (sl) 2021-09-27 2025-12-31 Terns Pharmaceuticals, Inc. Benzimidazolne karboksilne kisline kot agonisti GLP-1R
US12024507B2 (en) 2021-10-25 2024-07-02 Terns Pharmaceuticals, Inc. Compounds as GLP-1R agonists
AU2023224854A1 (en) 2022-02-23 2024-10-03 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
PE20250009A1 (es) * 2022-05-11 2025-01-07 Lilly Co Eli Composiciones de comprimidos de glp1
CN118791482B (zh) * 2022-11-20 2025-09-09 药康众拓(北京)医药科技有限公司 一种氘代吲唑类化合物、药物组合物及其应用
IL321043A (en) * 2022-12-15 2025-07-01 Sironax Ltd SARM1 modulators, their preparations and uses
IL321472A (en) * 2022-12-19 2025-08-01 Lilly Co Eli Process for the production of GLP1 RA and intermediates therefor
US20260217707A1 (en) * 2023-01-17 2026-07-30 Fochon Biosciences, Ltd. Glp-1r agonists and uses thereof
KR20250168210A (ko) 2023-02-16 2025-12-02 가셔브룸 바이오, 인크. 헤테로시클릭 glp-1 효능제
PE20252787A1 (es) 2023-04-07 2025-12-22 Terns Pharmaceuticals Inc Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica
CN119630663B (zh) * 2023-06-29 2025-10-21 韦恩生物科技有限公司 一种glp-1受体激动剂及其制备方法和用途
TW202506108A (zh) * 2023-06-30 2025-02-16 大陸商正大天晴藥業集團股份有限公司 含多稠環結構的化合物
WO2025011664A1 (zh) 2023-07-12 2025-01-16 歌礼制药(中国)有限公司 Glp-1r激动剂的制剂及其制备方法
AU2024317579A1 (en) 2023-07-28 2026-02-05 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Benzo nitrogen-containing heterocyclic derivative regulator, preparation method therefor and use thereof
WO2025026436A1 (zh) * 2023-08-02 2025-02-06 韦恩生物科技有限公司 一种含氮并环化合物及其制备方法和用途
EP4771001A1 (en) * 2023-08-31 2026-07-08 Gasherbrum Bio, Inc. Heteroaryl-heterocycloalkyl-based glp-1 agonists
EP4777197A2 (en) 2023-09-14 2026-07-22 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
WO2025097835A1 (zh) 2023-11-10 2025-05-15 重庆医药工业研究院有限责任公司 一种glp-1r激动剂化合物及其应用
WO2025103443A1 (zh) * 2023-11-16 2025-05-22 海思科医药集团股份有限公司 一种咪唑-2-酮衍生物及其在医药上的应用
KR20260118441A (ko) 2023-11-21 2026-07-30 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 헤테로시클릭 화합물, 이의 제조 방법 및 의약에서 이의 응용
WO2025109387A1 (en) * 2023-11-24 2025-05-30 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
AU2024394361A1 (en) * 2023-12-05 2026-06-18 Fortvita Biologics Inc. Glp-1 receptor targeting compounds and uses thereof
CN122438847A (zh) * 2023-12-14 2026-07-21 广东众生睿创生物科技有限公司 一种杂环glp-1受体激动剂及其应用
WO2025131043A1 (zh) * 2023-12-22 2025-06-26 石药集团百克(山东)生物制药股份有限公司 一类多环化合物及其用途
CN117447493A (zh) * 2023-12-25 2024-01-26 药康众拓(北京)医药科技有限公司 氘代吲哚嗪类化合物、药物组合物及其应用
CN117777111A (zh) * 2023-12-26 2024-03-29 上海苏博医药科技有限公司 一种Orforglipron关键中间体的合成方法及其中间体
CN122514525A (zh) * 2024-01-10 2026-08-04 海思科医药集团股份有限公司 一种四氢吡啶并吡唑衍生物及其在医药上的应用
WO2025158275A1 (en) 2024-01-24 2025-07-31 Pfizer Inc. Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds
CN120813584A (zh) * 2024-01-30 2025-10-17 海创药业股份有限公司 一种具有glp-1受体激动剂作用的小分子化合物及其用途
WO2025175249A1 (en) 2024-02-14 2025-08-21 Olema Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
WO2025176130A1 (zh) * 2024-02-19 2025-08-28 上海壹迪生物技术有限公司 一种含吡唑并环类化合物、其药物组合物及其用途
TW202600132A (zh) 2024-03-08 2026-01-01 美商安尼波那生物公司 用於治療肥胖症及提高減重之方法
TW202602880A (zh) * 2024-03-29 2026-01-16 美商拜歐美亞富成股份有限公司 雜環glp-1r促效劑
WO2025209515A1 (zh) * 2024-04-03 2025-10-09 广州市联瑞制药有限公司 一种glp-1受体激动剂及其制备方法和应用
WO2025237355A1 (zh) * 2024-05-17 2025-11-20 成都地奥九泓制药厂 一种glp-1受体激动剂化合物、其制备方法及其应用
WO2025247390A1 (zh) * 2024-05-31 2025-12-04 福佑泰生物制药公司 可用作glp-1r激动剂的杂双环化合物
WO2025259825A1 (en) 2024-06-12 2025-12-18 Eli Lilly And Company Glp-1 npa therapies for maintaining body weight loss or reduced hba1c levels following a prior glp-1 ra treatment
WO2025261454A1 (zh) * 2024-06-19 2025-12-26 上海翰森生物医药科技有限公司 一种含氮大环化合物衍生物调节剂及其制备方法和应用
WO2025264023A1 (en) * 2024-06-19 2025-12-26 Chong Kun Dang Pharmaceutical Corp. Glp-1 receptor agonist, and uses thereof
WO2026001866A1 (zh) * 2024-06-24 2026-01-02 联邦生物科技(珠海横琴)有限公司 一种glp-1受体激动剂及其应用
WO2026007995A1 (zh) * 2024-07-03 2026-01-08 成都地奥九泓制药厂 一种杂环类glp-1受体激动剂化合物、其制备方法及其应用
WO2026012416A1 (zh) * 2024-07-11 2026-01-15 江苏德源药业股份有限公司 杂环类化合物、药物组合物及其应用
WO2026012449A1 (zh) * 2024-07-12 2026-01-15 联邦生物科技(珠海横琴)有限公司 一种具有glp-1受体激动剂效应的杂环化合物及其应用
WO2026031819A1 (en) * 2024-08-06 2026-02-12 Insilico Medicine Ip Limited Novel compounds as glp-1r agonists and uses thereof
WO2026041075A1 (en) * 2024-08-21 2026-02-26 Gasherbrum Bio, Inc. Gpl-1 agonists
CN119100966B (zh) * 2024-09-02 2025-09-09 上海毕得医药科技股份有限公司 一种溴代吡咯甲酸甲酯的合成方法
WO2026055512A1 (en) * 2024-09-05 2026-03-12 Biomea Fusion, Inc. Combination of a menin inhibitor with a pyrazolopiperidine glp-1 receptor agonist for treating diabetes and obesity
WO2026052129A1 (zh) * 2024-09-09 2026-03-12 中国科学院上海药物研究所 多环杂芳烃类glp-1受体激动剂
WO2026086876A1 (zh) * 2024-10-23 2026-04-30 郑州同源康医药有限公司 作为glp-1r激动剂的化合物
CN119372270A (zh) * 2024-10-25 2025-01-28 成都安迈博生物医药有限公司 一种通过酶催化构建Orforglipron吡喃环手性的方法
WO2026096330A1 (en) * 2024-10-28 2026-05-07 Merck Sharp & Dohme Llc Glp-1 receptor agonists and methods of use
WO2026092583A1 (en) 2024-10-30 2026-05-07 Ascletis Pharma (China) Co., Limited Thr-beta modulators, alone or in combination with glp-1r\gipr\gcgr modulators for the treatment of metabolic diseases and alopecia areata diseases
WO2026092580A1 (en) 2024-10-30 2026-05-07 Ascletis Pharma (China) Co., Limited Glp-1r\gipr\gcgr modulator in combination with thr-beta modulator for treatment of metabolic diseases
WO2026092581A1 (en) 2024-10-30 2026-05-07 Ascletis Pharma (China) Co., Limited Thyroid hormone receptor beta modulator alone or in combination with a modulator of glp-1r, gipr or gcgr, for use in the treatment of obesity or overweight or for treating alopecia areata
WO2026093542A1 (en) * 2024-11-01 2026-05-07 Astrazeneca Ab Glp1r agonist and sglt-2 inhibitor combination therapy
WO2026093539A1 (en) * 2024-11-01 2026-05-07 Astrazeneca Ab Methods of treating or managing obesity
WO2026093541A1 (en) * 2024-11-01 2026-05-07 Astrazeneca Ab Dosage regimens for azd5004
WO2026093537A1 (en) * 2024-11-01 2026-05-07 Astrazeneca Ab Methods of treating diabetes
WO2026093543A1 (en) * 2024-11-01 2026-05-07 Astrazeneca Ab Glp1r agonist and pcsk9 inhibitor combination therapy
CN119101040B (zh) 2024-11-08 2025-03-21 杭州澳赛诺医药技术有限公司 一种通过去对称化合成芳基取代的手性四氢吡喃环的方法
WO2026103930A1 (zh) * 2024-11-18 2026-05-21 西藏海思科制药有限公司 一种咪唑-2-酮衍生物及其在医药上的应用
WO2026130384A1 (zh) * 2024-12-17 2026-06-25 上海翰森生物医药科技有限公司 一种苯并含氮杂环类衍生物、其制备方法和应用
WO2026153543A1 (zh) * 2025-01-20 2026-07-23 歌礼制药(中国)有限公司 Glp-1r激动剂的晶型及其制备方法和用途
WO2026158353A1 (zh) * 2025-01-23 2026-07-30 联邦生物科技(珠海横琴)有限公司 具有glp-1受体激动剂效应的杂环化合物及其应用
WO2026158377A1 (zh) * 2025-01-24 2026-07-30 联邦生物科技(珠海横琴)有限公司 具有glp-1受体激动剂效应的杂环化合物及其应用
WO2026165082A1 (en) * 2025-01-28 2026-08-06 Ambrosia Biosciences Inc. Small molecule glp-1 agonists
CN120309500B (zh) * 2025-06-19 2025-08-15 南昌大学 奥格列龙原料中间体及合成方法与奥格列龙原料合成方法
CN121949295A (zh) * 2026-03-31 2026-05-01 成都安迈博生物医药有限公司 一种构建aleniglipron关键中间体的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JP6278472B2 (ja) 2013-02-27 2018-02-14 塩野義製薬株式会社 Ampk活性化作用を有するインドールおよびアザインドール誘導体
JOP20190060A1 (ar) * 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
JP7461104B2 (ja) * 2017-11-29 2024-04-03 中外製薬株式会社 Glp-1受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
JP2021514982A (ja) 2018-02-28 2021-06-17 ノバルティス アーゲー インドール−2−カルボニル化合物及びb型肝炎治療のためのそれらの使用

Also Published As

Publication number Publication date
JP7795064B2 (ja) 2026-01-07
CA3186217A1 (en) 2022-01-27
JP2023534983A (ja) 2023-08-15
PH12023550130A1 (en) 2024-06-24
US20250059192A1 (en) 2025-02-20
AU2025237942A1 (en) 2025-10-16
US12037339B2 (en) 2024-07-16
AU2021311567B2 (en) 2025-07-10
CN122461300A (zh) 2026-07-28
CN116390926A (zh) 2023-07-04
CN122483082A (zh) 2026-07-31
CN122398793A (zh) 2026-07-17
CO2023001407A2 (es) 2023-02-16
IL299704B1 (en) 2026-07-01
KR20260040657A (ko) 2026-03-25
US11584751B1 (en) 2023-02-21
UA130727C2 (uk) 2026-04-29
EP4182020A1 (en) 2023-05-24
AU2021311567A1 (en) 2023-02-16
CN122516176A (zh) 2026-08-07
JP2026035735A (ja) 2026-03-04
CN122398794A (zh) 2026-07-17
US20230051320A1 (en) 2023-02-16
MX2023000943A (es) 2023-02-22
BR112023000932A2 (pt) 2023-10-03
IL328692A (en) 2026-07-01
IL299704A (en) 2023-03-01
JP7569443B2 (ja) 2024-10-17
KR20230048056A (ko) 2023-04-10
WO2022017338A1 (en) 2022-01-27
CN116390926B (zh) 2026-05-19
CN122516177A (zh) 2026-08-07
CN122351233A (zh) 2026-07-10
JP2025004124A (ja) 2025-01-14
KR102936860B1 (ko) 2026-03-12
PE20230854A1 (es) 2023-05-29

Similar Documents

Publication Publication Date Title
CO2023001407A2 (es) Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y métodos de uso de los mismos
CO2026005655A2 (es) Inhibidor de pan-kras y uso del mismo en medicinas
CR20220281A (es) Derivados de pirazolilo útiles como agentes anti-cancerígenos
PH12019500395A1 (en) Amino-pyrrolopyrimidinone compounds and methods of use thereof
ECSP22018571A (es) Degradadores bifuncionales de brd9 y sus métodos de uso
PE20240881A1 (es) Uso de un inhibidor de la ezh2 en la preparacion de farmacos para el tratamiento del linfoma de linfocitos t
MX2009001660A (es) Compuestos de 2,5-dihidroxibenceno para el tratamiento de psoriasis.
AR079208A2 (es) Inhibidores de la actividad de proteina tirosina quinasa, composicion y uso de dichos inhibidores para la preparacion de un medicamento para tratar una enfermedad, trastorno o condicion oftalmica
UY39625A (es) Derivados tricíclicos útiles como inhibidores de parp7
ECSP22032016A (es) Inhibidor de irak y método de preparación para el mismo y uso del mismo
AR119318A1 (es) Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1
MX2021015543A (es) Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo.
CL2024003460A1 (es) Derivados de oxoindolinil amida para inhibir nlrp3 y usos de los mismos.
CO2022008616A2 (es) Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma
MX2024012471A (es) Inhibidores de cinasas dependientes de ciclina 9 (cdk9)
CL2019000727A1 (es) Compuestos de indazol para usar en lesiones de tendones y/o ligamentos.
CO2026000093A2 (es) Composiciones farmacéuticas para inhibidores de la cinasa nek7
MX2022005199A (es) Inhibidores de ssao y uso de los mismos.
PE20240822A1 (es) Inhibidores de vmat2 y metodos de uso
MX2022005415A (es) Compuesto de imidazolidinona, metodo de preparacion del mismo y uso del mismo.
CO2024012868A2 (es) Derivado de imidazopiridazina, y método de preparación del mismo, composición farmacéutica del mismo y uso del mismo
ECSP088237A (es) Derivados de quinolina y uso como agentes antitumor
AR134792A1 (es) Inhibidor de tyk2 y uso del mismo
AR131909A1 (es) Compuestos macrocíclicos de aminopiridina como inhibidores de egfr
AR124698A1 (es) Derivados tricíclicos útiles como inhibidores de parp7